Ting C. Wu

Xiangan South Road
Xiamen, China

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 159 publications

Resource Dependence， Green Technology Innovation， and Carbon Emission in Coal- resource-based Cities

Resource Dependence， Green Technology Innovation， and Carbon Emission in Coal- resource-based Cities

Journal: Huan jing ke xue= Huanjing kexue

Published: July 20, 2026

Tumorigenesis of well-differentiated and dedifferentiated liposarcoma: 12q amplicon architecture, oncogenic cargo, and evolutionary progression.

Tumorigenesis of well-differentiated and dedifferentiated liposarcoma: 12q amplicon architecture, oncogenic cargo, and evolutionary progression.

Journal: Cancer metastasis reviews

Published: May 23, 2026

Surmounting the electronic paradox: A "push-pull" mediated Ru-Co3O4/FeOOH architecture for overall water splitting.

Surmounting the electronic paradox: A "push-pull" mediated Ru-Co3O4/FeOOH architecture for overall water splitting.

Journal: Journal of colloid and interface science

Published: May 23, 2026

Hepatitis E virus seroepidemiology among Malaysian blood donors: Prevalence and associated risk factors.

Hepatitis E virus seroepidemiology among Malaysian blood donors: Prevalence and associated risk factors.

Journal: Vox sanguinis

Published: April 19, 2026

Genetically programmed engineered nanodevices trigger cascade reinforcement between AMPK and cGAS-STING activation for colon cancer sonoimmunotherapy.

Genetically programmed engineered nanodevices trigger cascade reinforcement between AMPK and cGAS-STING activation for colon cancer sonoimmunotherapy.

Journal: Biomaterials

Published: April 05, 2026

Biomimetic dual-driven STING nanoagonist orchestrates neoadjuvant mild photo-immunotherapy for fibrosarcoma.

Biomimetic dual-driven STING nanoagonist orchestrates neoadjuvant mild photo-immunotherapy for fibrosarcoma.

Journal: Materials today. Bio

Published: February 27, 2026

Immunogenicity and Safety of Two-dose Schedules With Different Intervals of an ORF7-deficient Live Vaccine Candidate for Varicella: A Randomized, Double-blind, Controlled, Phase 2b Trial.

Immunogenicity and Safety of Two-dose Schedules With Different Intervals of an ORF7-deficient Live Vaccine Candidate for Varicella: A Randomized, Double-blind, Controlled, Phase 2b Trial.

Journal: The Pediatric infectious disease journal

Published: February 18, 2026

Reply to: Comments on "Type- and age-specific natural history of high-risk human papillomavirus infections in healthy women: A prospective cohort study in China".

Reply to: Comments on "Type- and age-specific natural history of high-risk human papillomavirus infections in healthy women: A prospective cohort study in China".

Journal: International journal of cancer

Published: February 10, 2026

Identification of a surface-accessible tegument protein bearing a neutralizing epitope in varicella-zoster virus.

Identification of a surface-accessible tegument protein bearing a neutralizing epitope in varicella-zoster virus.

Journal: Antiviral research

Published: January 22, 2026

Identification of a Surface-Accessible Tegument Protein Bearing a Neutralizing Epitope in Varicella-Zoster Virus.

Identification of a Surface-Accessible Tegument Protein Bearing a Neutralizing Epitope in Varicella-Zoster Virus.

Journal: Antiviral research

Published: January 22, 2026

Phenotypic transition in retroperitoneal liposarcoma: Bridging well-differentiated and dedifferentiated subtypes through genomics, epigenetics, and the tumor microenvironment.

Phenotypic transition in retroperitoneal liposarcoma: Bridging well-differentiated and dedifferentiated subtypes through genomics, epigenetics, and the tumor microenvironment.

Journal: Biochimica et biophysica acta. Reviews on cancer

Published: December 10, 2025

Efficacy, safety, and immunogenicity of an Escherichia coli-produced nine-valent human papillomavirus vaccine: a multicentre, double-blind, randomised, controlled, phase 3 trial.

Efficacy, safety, and immunogenicity of an Escherichia coli-produced nine-valent human papillomavirus vaccine: a multicentre, double-blind, randomised, controlled, phase 3 trial.

Journal: The Lancet. Infectious diseases

Published: November 28, 2025

Showing 1-12 of 159

Last Updated: 09/26/2026